5 Reasons Why You Must Attend This Event!*
*Only for those looking to improve their MedTech products’ market access.
In the increasingly cost-contained world of medical device market access, Payers (including ministries of health, insurers private & public, hospitals and local governments) are seeking to justify investment in new medical technologies. Health Technology Assessment (HTA) agencies are now widely spreads across Europe assess new technologies and interventions not only on the grounds of clinical effectiveness, but also based on cost-effectiveness, cost-utility and cost-benefit, to ensure the payers’ limited funds are well invested. This HTA and value demonstration requirement has evolved the “commercialisation” landscape of medical devices across the world and this next barrier is one that all medical device companies seeking to gain reimbursement and approval from payers and tendering bodies, need to overcome.
The variety of commercial channels, customers and payers within the medical device space is as diverse as the different business models being used for the different product types (e.g. Imaging Vs Surgical products) and only increases the complexity and specificity of the “value message” which needs to well-delivered, in order to ensure an optimal outcome. This three-day event is the “must-attend” event for all senior directors at medical device companies who are looking to enhance market access for their products.
The first day will feature Europe’s leading payers, HTAs and market access KOLs discussing what they want to see from medical device manufacturers bringing new products to the market and will be a perfect opportunity to engage these key stakeholders. The second day of the event will contrast market access strategies for medical devices in key markets to enable market access and product managers to sequence and prioritise their product launch.
The different stakeholders involved in each market access process and the varying ways to engage them and demonstrate “value” for your technologies will be show from leading companies in the field for you to learn and benchmark from. Participants will leave this event armed with real-life, best practice examples of what is working and not working for your specific product type; what Payers and HTAs consider as essential and “nice to have” information to create “value”; and will have established relationships with the peers from the industry as well as influential decision-makers & KOLs in this sector. We look forward to meeting you in Berlin!
Programme Officer European Commission eHealth, Well-being and Ageing (DG Connect)
European Commission
Legal & Policy Officer
European Commission
Director, Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member, EUnetHTA
Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS
Senior Scientific Adviser
NICE - National Institute for Health and Care, UK
Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy
Director of Research and Education, Professor in Medical Biophysics
Region Jämtland Härjedalen, Östersund, Sweden
Head of Clinical Engineering Service
Humanitas Research Hospital, Italy
Member
RWE4Decisions - RIZIV/INAMI led HTA/Payer Initiative
Chief of development and communications
Center of Healthcare Quality Assessment and Control, The Ministry of Health of the Russian Federation
Associate Professor, Economic Evaluations in Health Care
Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)
Erasmus University Rotterdam, Netherlands
Senior Health Economist
Health Technology Wales, UK
Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions
Senior Advisor
MedTech Europe
Manager Market Access and Economic Policies
MedTech Europe, Belgium
Director Value-Based Healthcare
ValueConnected
Vice President, Innovation Program Manager
Philips Research
Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe
Vice President Communications, Europe, Middle East & Africa
Medtronic
Senior Director, Market Access
Roche Tissue Diagnostics, USA
Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany
Global Director Scientific Communications | Medical Affairs
Medtronic, France
Program Director
Medtech4Health, Sweden
Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University
Senior Vice President, Global Market Access
Inspire Medical Systems
Senior Director DACH, Payers & Health Economics
Coloplast
Senior Manager, Global Pricing & Competitive Portfolio Analytics Team
Philips Healthcare
Sr. Director Marketing & Academy Europe
Arjo, Europe
Hospital Economics - Sr. Manager Strategic Marketing Monitoring & Analytics and Therapeutic Care
Philips, Germany
Director Reimbursement Germany
CytoSorbents Corporation
Global Pricing Manager, SBU Oncology, Pharmaceuticals
Bayer, Germany
CEO and Founder
ValueConnected
Director of European Operations
ValueConnected
President
Boston Healthcare, USA
Vice President
Boston Healthcare
Principal and Founder
Hull Associates
Director, Life Sciences
Huron Consulting
Global healthcare systems are evolving daily. At a time of increased health economic reform, ageing populations and budget austerity, leaders in medical technology look to achieve optimal market access and commercialization of their products. As payers worldwide demand more value for money on the medical devices they fund, the importance of achieving patient access by demonstrating cost effectiveness and enhanced health outcomes is of the utmost importance. With payers in both developed and developing countries under extreme budgetary pressure, we will provide a platform for attendees to examine how health technologies are assessed, tough decisions are made and how we define “value”. This exclusive forum is the opportunity to meet and network with a broad spectrum of senior representatives who wish to encourage innovation whilst managing a limited budget.
CEO and Founder
ValueConnected
Director, Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member, EUnetHTA
Senior Scientific Adviser
NICE - National Institute for Health and Care, UK
Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions
Director, Life Sciences
Huron Consulting
Programme Officer European Commission eHealth, Well-being and Ageing (DG Connect)
European Commission
Director, Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member, EUnetHTA
Senior Scientific Adviser
NICE - National Institute for Health and Care, UK
Senior Advisor
MedTech Europe
Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany
Manager Market Access and Economic Policies
MedTech Europe, Belgium
Director Value-Based Healthcare
ValueConnected
Principal and Founder
Hull Associates
Vice President, Innovation Program Manager
Philips Research
Vice President
Boston Healthcare
Programme Officer European Commission eHealth, Well-being and Ageing (DG Connect)
European Commission
Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS
Director Value-Based Healthcare
ValueConnected
Vice President, Innovation Program Manager
Philips Research
Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions
Medical device firms are increasingly under pressure from payers, HTA agencies, healthcare providers and other stakeholders to provide real evidence of their product’s benefit. Increasingly, especially when a technology is expensive, the CE Mark alone is no longer sufficient to gain market access. Robust health economic evidence demonstrating the clinical and economic value of a device is either becoming mandatory, or at least can be a source or competitive advantage to differentiate apparently similar products. Evidence can still be generated from scientific publications, but on top of this, sophisticated and expensive clinical trials and even real-world studies are now being designed and implemented. Getting the trial design right from the beginning is essential, so that the right research questions are being asked and robust methodologies are used to demonstrate improved health outcomes. Protocols must also be operationally feasible to ensure not just messy data is developed, but real evidence so that payers can gain insights into the value and make better reimbursement decisions. This stream will detail how clinical, real-world, economic and scientific publication data sources can be integrated to prepare a sophisticated value dossier to demonstrate value to payers and other key stakeholders.
Vice President
Boston Healthcare
CEO and Founder
ValueConnected
Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy
Head of Clinical Engineering Service
Humanitas Research Hospital, Italy
Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany
Global Director Scientific Communications | Medical Affairs
Medtronic, France
Director of European Operations
ValueConnected
Senior Vice President, Global Market Access
Inspire Medical Systems
Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University
Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe
Hospital Economics - Sr. Manager Strategic Marketing Monitoring & Analytics and Therapeutic Care
Philips, Germany
Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy
Global Director Scientific Communications | Medical Affairs
Medtronic, France
Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University
Senior Vice President, Global Market Access
Inspire Medical Systems
Chief of development and communications
Center of Healthcare Quality Assessment and Control, The Ministry of Health of the Russian Federation
Medical devices are coming under greater scrutiny by payers and hospital procurement directors than ever before. Manufacturers today are required to understand and quantify the cost savings for hospitals & payers based on the direct & indirect savings their products deliver. Changes to the European directives on public procurement are directly impacting the way medical device companies communicate and market their products via public procurement channels for high-value products. This one-day event will bring together procurement experts from European Policy-level, leading industry associations, hospitals (procurers) and the MedTech industry to join the conversation and to understand better the needs of their strategic partners. It will enable all participants the opportunity to benchmark procurement processes and tender approaches at a regional, local and hospital perspective. Medical device companies will understand in greater detail what their customers are looking for as drivers of value, and what is attractive for them to enhance their tender and public procurement strategy.
Director Value-Based Healthcare
ValueConnected
Legal & Policy Officer
European Commission
Director of Research and Education, Professor in Medical Biophysics
Region Jämtland Härjedalen, Östersund, Sweden
Senior Advisor
MedTech Europe
Program Director
Medtech4Health, Sweden
Senior Director DACH, Payers & Health Economics
Coloplast
Senior Manager, Global Pricing & Competitive Portfolio Analytics Team
Philips Healthcare
Most MedTech companies operate in a commoditized business landscape, if you sell products it will always be about price. In order to grow in a sustainable way MedTech companies need to transform from suppliers into partners. It’s all about in detail understanding how products are being used, what the processes look like, how is care and cure being financed and what is the customers strategy. Only by understanding these components, the willingness to adapt the total offering and organization and having a long term view in mind, MedTech companies are able to grow their business in a sustainable way.
Sr. Director Marketing & Academy Europe
Arjo, Europe
Legal & Policy Officer
European Commission
Senior Advisor
MedTech Europe
Program Director
Medtech4Health, Sweden
Senior Director DACH, Payers & Health Economics
Coloplast
Sr. Director Marketing & Academy Europe
Arjo, Europe
As the product nature of personalised medicines and companion diagnostics becomes increasingly complex, so too is the market access process surrounding these essential tests and procedures. These diagnostics bring unique market access & procurement challenged through DRG coding, bundling and procurement for laboratory test service providers. As the cost of these tests increases, so too does the requirement to justify the value and ROI to all necessary stakeholders. For companion diagnostics, partnering and strategic alliances with pharma (if not already vertically integrated) provides a strong market access vector, but achieving this has been proven difficult with only a handful of successful examples to date. As payers, procurers, HMOs and purchasers demand more evidence to justify costs, the challenges surrounding market access have never been greater. This one-day stream will discuss the market access challenges affecting personalised medicine and companion diagnostics globally with case studies of successful launches and cautionary tales of those which were not, to provide benchmarking and learning opportunities for all participants.
President
Boston Healthcare, USA
Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe
Associate Professor, Economic Evaluations in Health Care
Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)
Erasmus University Rotterdam, Netherlands
Senior Director, Market Access
Roche Tissue Diagnostics, USA
Global Pricing Manager, SBU Oncology, Pharmaceuticals
Bayer, Germany
Senior Director, Market Access
Roche Tissue Diagnostics, USA
Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe
Global Pricing Manager, SBU Oncology, Pharmaceuticals
Bayer, Germany
Surgical device reimbursement & market access now requires more data and value justification than ever before. The good news is that with value adding benefits (minimally invasive procedures; less frequent implant replacement; faster recovery times and greater long-term health benefits), manufacturers have a real opportunity to show what their product can deliver in terms of cost effectiveness to HTAs & Payers. The requirement for existing products to defend their place in the market as well as new products to show true innovation is now a reality. With the data alone now telling the story, it provides large medical device manufacturers the ability to permanently solidify their place in the market and it gives smaller device companies the ability to break into this massive marketplace. This one-day stream will give best practice examples on value demonstration and market access approaches for surgical devices and implantables.
Principal and Founder
Hull Associates
Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University
CEO and Founder
ValueConnected
Vice President Communications, Europe, Middle East & Africa
Medtronic
Director Reimbursement Germany
CytoSorbents Corporation
Vice President Communications, Europe, Middle East & Africa
Medtronic
Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University
CEO and Founder
ValueConnected
Director Reimbursement Germany
CytoSorbents Corporation
Before our panel of Subject Matter experts and practitioners, participants will prepare short briefs to demonstrate the value of several fictional case study products to a panel for approval.
As all MedTech market access industry practitioners know, you only get one chance to make a great first impression on payers and procurement decision makers, so this workshop will allow participants to practice their presentations in a safe environment. Assessors will look at: Content, Presentation skills, Style and Evidence Use in order to give constructive feedback.
Participants will be grouped into product specific areas which will enable them to tailor their learnings for their products, including:
- Diagnostic Imaging/Capital Equipment (Robotic Surgical Device & HemoDialysis Machine)
- Surgical & implantable devices (Transarterial Valve Replacer & Femoral Stem Implant)
- Hospital Consumables (CSII Insulin Pump & Companion Diagnostic)
Participants will compose and deliver presentations to our panel of Payers/Purchasers to bring the learnings all together.
Principal and Founder
Hull Associates
Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS
Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy
Member
RWE4Decisions - RIZIV/INAMI led HTA/Payer Initiative
Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany
Senior Health Economist
Health Technology Wales, UK
Participants will be given a fictional product to develop an argument for, to present to our panel of Payers, based on the product area best suited to their daily practice
Area 1: High Value Diagnostic & Capital Equipment - PICASSO
Area 2: Surgical & Implantable Devices - TVAR
Area 3: Hospital Consumable/OTC Devices - CONNEX insulin Pump
Participants will be given a fictional product to develop an argument for, to present to our panel of Payers, based on the product area best suited to their daily practice
Area 1: High Value Diagnostic & Capital Equipment - Reno-Matic Home Dialysis Machine
Area 2: Surgical & Implantable Devices - Fem-X Femoral Stem
Area 3: Companion Diagnostic
Device manufacturers & distributors:
Marketing, Market-access, Business Development, Country Managers, Health Economics, Pricing & Reimbursement, Government & Stakeholder Relations, Regulatory Affairs
Stakeholders:
Health Plans & Insurers, Payers, Health Technology Assessors, Hospitals, Health Ministry, Regulatory Agencies, Independent Health Economists, Academics, Physicians and Patient Groups
Solution providers & consultants:
CEOs, Business Development, Senior Consultants, Global and Regional Heads, Independent Academics, Health Economists
The MedTech Access Leaders Forum will also have the PharmAccess Leaders Forum co-located. That event is for senior directors of Market Access at pharma and biotech organisations and will have a specific focus on Specialty Pharma products, Innovative Market Access Agreements and Precision Medicine Market Access. It will also feature a Mock Payer Panel Workshop with Real Payers giving feedback to participants and an additional workshop on Managed Entry Agreements & Risk Sharing approaches. For more information click the banner below:
Programme Officer European Commission eHealth, Well-being and Ageing (DG Connect)
European Commission
Birgit Morlion is an engineer (PhD) with a mission to make digital health come true. Over the last 15 years she has been actively involved in eHealth research and facilitating the adoption of digital innovation in health care in Belgium. She was part of the start-up team of the Flemish digital research and innovation institute iMinds; helping to bridge the gap between research and exploitation of results. She also occupied strategic advisory roles for the Flemish and the Belgian Ministers of health in the domain of medical data-exchange and patient access to electronic medical records. In May 2017 she joined the eHealth, well-being and ageing unit of the European commission (DG Connect) where she works on the digital transformation of health and care in the Digital Single Market more specifically with a focus on mobile health (mHealth), integrated care and active and assisted living.
Legal & Policy Officer
European Commission
An holds a Belgian law degree issued by the University of Leuven as well as a master of laws issued by the Albert-Ludwig University of Freiburg im Breisgau (Germany). Prior to the Commission An has worked in the area of health law, first an assistant at the University of Leuven and thereafter in the private sector. Since more than twelve years, An has been working for the Commission dealing with different internal market issues. Since three years she works in the field of public procurement. In particular, she deals with Austrian and German complaints. She also is responsible for the policy work related to the application of public procurement rules in the health and waste management sector.
Director, Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member, EUnetHTA
Claudia Wild was born in 1960. Studies of communications & psychology at the University of Vienna and of political sciences at the Ohio University in Athens/Ohio/USA. Graduation at the University of Vienna: Doctor of Philosophy in 1985. 1985-1988 Research Associate on “media impact on cognitions” at the Institute for Communications and Political Science at the University of Nuernberg/Germany and other freelance media impact research projects. 1989-2006: Senior Researcher at the Institute of Technology Assessment at the Austrian Academy of Sciences and development in the research field Health Technology Assessment in Austria. Since April 2006 she is Director of the Ludwig Boltzmann Institute for HTA. In 2009 habilitation/postdoctoral lecture qualification in social medicine (Medical University Graz) on the topic of “resource allocation in health-care systems”. She is member of several national and international organizations, teaches HTA at universities and private colleges and is an active reviewer for several international journals in the field of HTA.
Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS
Diar is the Associate Director of Medicines Optimisation at Dartford, Gravesham and Swanley and Swale CCGs. Diar takes the lead on the provision of medicines optimisation on all matters relating to medicines use, prescribing and the provision of pharmaceutical services to the CCGs. His interests have been focused on combatting inappropriate polypharmacy with the use of healthcare data analytics.
Diar also sits on the NICE technology appraisal committee, analysing HTA applications for the NHS.
Previously, he has worked as Medicine Optimisation Pharmacist at Medway CCG, a tutor at the Centre for Pharmacy Postgraduate Education (CPPE) based at the University of Manchester and a pharmacist clinical advisor in NHS 111.
Diar holds a Masters in Pharmacy and a Masters in Health Economics and Health Policy."
Senior Scientific Adviser
NICE - National Institute for Health and Care, UK
Chris currently works in the Scientific Advice team at NICE which provides advice helping companies to prepare for NICE evaluations and to support discussions with payers and commissioners to enable market access. He has also previously worked in the NICE medical technologies evaluation programme (MTEP) and the technology appraisals programme (TAP). Chris also has experience working in a healthcare consultancy where he worked on a variety of health technology assessment and market access projects. Chris has a Master’s degree in Biological Chemistry from the University of Sheffield, and completed a PhD in biological sciences from the University of Manchester.
Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy
Tom Jefferson is a physician, epidemiologist and researcher. Tom’s field of expertise is evidence synthesis applied to Cochrane and other systematic reviews and Health Technology Assessment. Tom is a Senior Associate Tutor at the University of Oxford, a researcher at the Nordic Cochrane Centre and the scientific coordinator for the production of HTA reports on non-pharmaceuticals for Agenas, the Italian National Agency for Regional Healthcare.
Director of Research and Education, Professor in Medical Biophysics
Region Jämtland Härjedalen, Östersund, Sweden
Göran Larsson has a Ph.D. in medical biophysics from Umea University. After his Ph.D. Göran joined University of Cambridge, UK for a three year Post.Doc period. In 2004 he returned to Umea University where he worked as a university teacher and researcher until 2012 when he moved to Östersund for his current position as Director of Research and Education in Region Jämtland Härjedalen. In 2014 he become Professor in medical biophysics. Göran Larsson is interested in eHealth/mHealth solutions and is responsible for innovation processes related to digitalization of healthcare in his organization.
Head of Clinical Engineering Service
Humanitas Research Hospital, Italy
Paolo joined Humanitas Research Hospital in July 2017. He graduated from University of Naples Federico II with a Bachelor’s degree in Biomedical Engineering. He completed his Master’s degree in Clinical Engineering at the same University and subsequently completed his second level Master’s degree in Health Economics at SDA Bocconi School of Management. Prior to joining Humanitas Research Hospital, Paolo worked for 3 years as Clinical Engineer and Operation Manager at PLV Fatebenefratelli private Group of Hospitals.
Member
RWE4Decisions - RIZIV/INAMI led HTA/Payer Initiative
Karen Facey has a PhD in Statistics and has worked as a senior statistician in pharmaceutical companies and the MHRA, the UK medicines regulatory agency. In 2000 she was founding Chief Executive of the first national health technology assessment (HTA) Agency in Scotland and since 2003 has been an independent consultant on HTA and patient involvement. She has been a board member of a health board (payer/provider) in Scotland and is a member of the Scottish HTA appraisal committee for non-medicines HTA. She pursues research interests as an Honorary Research Fellow at the University of Edinburgh in assessment of therapies for rare diseases and Managed Entry Agreements. She is part of the ORPH-VAL working group including regulators, HTA experts and industry. Karen is lead editor on a book on patient involvement in HTA published by Springer in May 2017 and in 2014 she was named in the top 100 practicing scientists in the UK.
Chief of development and communications
Center of Healthcare Quality Assessment and Control, The Ministry of Health of the Russian Federation
Dr. Musina is a Chief of Development and Communications at the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation.
Dr. Musina is also an Associate Professor at the Department of Pharmacology Sechenov University. Dr. Musina was a postdoctoral fellow and obtained a Master of Science Diploma in Economic Evaluation for Health Technology Assessment at the University of York, UK (2016).
She’s an author of educational and methodical manuals for pharmacists and more than 30 research publications, she is also a member of the editorial board of the scientific journal "Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology".
Associate Professor, Economic Evaluations in Health Care
Erasmus School of Health Policy and Management (ESHPM)
Institute for Medical Technology Assessment (iMTA)
Erasmus University Rotterdam, Netherlands
Dr Hakkaarts’ interest in the relation between cost and effects in health care is the result of a broad interest to explore economic evaluations from a societal perspective and report outcomes that helps decision making in health care on different levels. She was involved in the developed questionnaires to measure cost from a societal perspective. The iMTA Medical Cost Questionnaire (iMCQ), the iMTA Productivity Cost Questionnaire (iPCQ) and the Treatment inventory of Costs in Psychiatric Patients (TiC-P) were developed. Her special interest is to develop a research program for economic evaluations in mental health care and orphan diseases. Therefore, she works closely with a large number of other national and international institutions. Dr Hakkaart supervises PhD students on this topic. She is co-promoter of a PhD student conducting cost effectiveness analyses on orphan drugs. Recently, she supervised the update of the Dutch manual for costing studies in economic evaluations supported by the National Health Institute (ZiN). A collaborative partnership with TOPGGz, a foundation for highly specialized psychiatric care, was initiated. In this context, she developed a method to develop ‘Decision Tools’ (DT) to identify severe and complex patients for top clinical specialized care. Validated DTs for personality disorders, eating disorders, depression and anxiety were developed. She guides and teaches Bachelor and Master students in economic evaluations.
Senior Health Economist
Health Technology Wales, UK
Tom specialises in economic modelling and has interests in the health econometrics of advanced therapies, he leads the health economics team at health technology wales. Within HTW he is responsible for the development and delivery of the technology evidence appraisals which lead to national guidance reports. Tom is currently evaluating the optimisation of cancer treatment pathways and is developing market access strategies for cell and gene therapies. Previously he worked for the Swansea Centre for Health Economics performing HE evaluations alongside clinical trials. He has qualifications in Economics from Swansea university (BSc , MSc, PhD) and in health economics (PGCert) from Aberdeen University.
Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions
Gottfried Endel, M.D., is the Head of the department of Evidence Based Health Care in the Main Association of Austrian Social Insurance Institutions. He joined the Austrian Social Insurance Authority for Business (SVA) in 1988 and served in the department for Prior Authorization and Physicians’ Control. Gottfried is a General Practitioner since 1988.
Senior Advisor
MedTech Europe
Graduated in 1987 as Electro-Mechanical Engineer with specialty electronics at the Catholic University of Leuven, followed by a post-graduate year of Master of Business Administration. A first working experience in the field of Clinical Engineering at Intermedics, a US based pacemaker and implantable defibrillator company. Build out and directed the European Clinical Research Department. Holder of 5 patents in field of cardiac stimulation in health failure and co-author of 3 publication in this period. Joined in 1999 Medtronic to head the European Heart Failure clinical outcomes & research department ensuring the development of Clinical and Health Economic Outcome Evidence. In close cooperation with Clinical Community landmark trials were designed, conducted and published in the Int’l journals as New England Journal of Medicine, Circulation and others with a high impact factor. A contribution of to 8 publication of which 3 as co-author. This evidence based ensured : Cardiac Resynchronization therapy obtained a class I indication level of evidence A in clinical guidelines; Cardiac Resynchronization therapy obtained a positive HTA appraisals for the full population studied . In September 2008, took on the responsibility of Assistant Director Health Economics, EurMEA at Alcon in the field of Ophthalmology for both medicinal and medical devices ranging from treatments of bacterial conjunctivitis, dry eye and glaucoma to Implantable Ocular Lenses. Developed comprehensive Patient Report Outcomes instrument to support patient diagnosis and assessing the outcome value of dry eye treatment to patients. Supported and co-authored to an additional 8 publications. As of 1st May 2012, head of Market Access and Economic Policies for MEDTECH EUROPE to strive to balanced pro-innovation policies and to shift to a Value based Access model within EU frameworks. Initiatives in dialogue with procurers, payer, HTA member states representatives and other stakeholders are MEAT Value Based Procurement, Value of Diagnostic Information, Modern HTA Cooperation in Europe, new evidence and financing schemes to shift to access of medical technologies of value for patients, healthcare, society and our economy.
Director Value-Based Healthcare
ValueConnected
Richard has over 15 year of industry experience across both the Healthcare and Financial services sectors. Richard is currently the Director of Value Based Healthcare at ValueConnected, a company focusing on implementing Value Based Healthcare. Richard was formerly at Becton Dickinson, where held various senior roles in Market Access & Pricing. Richard is currently the Co-Chair of the ISPOR Medical Devices Interest Group, where he also teaches the short course on Market Access for Medical Devices. Richard is also the co-chair of HTAi Medical Device Interest Group, where he is frequently called on as a guest speaker. Richard is currently the industry Advisor to COMED, an EU funded consortium measuring outcomes and costs in medical devices. Richard graduated from SDA Bocconi in Italy with a Masters in Healthcare Management, Economics & Policy, as well as from the University of Guelph in Canada, in Management Economics & Public Policy.
Vice President, Innovation Program Manager
Philips Research
Hans Hofstraat is Innovation Program Manager at Philips Research, a position he has held since 2009. As Innovation Program Manager, Hans works with teams within Philips Research, and with colleagues in Business and Markets, on innovations in the area of Oncology, Neurology, and Universal Access to Care, combining deep clinical insights with the opportunities offered by digital healthcare. Together with partners within and beyond Philips, Hans is passionate about identifying major needs in the health-technology domain, and to address these by developing meaningful solutions underpinned by proven outcomes. His aim is always to achieve innovations that broaden access to appropriate care and improve quality of life for patients and healthcare professionals.
Hofstraat holds several positions in (inter)national advisory bodies. Amongst others, he is a member of the Dutch Sounding Board for Horizon 2020, contributing to work on Health, Demographic Change and Well-being. He is a member of the Steering Committee and co-initiator of the big data initiative of Top Sector Life Sciences & Health. He is also a member of the Management Team of the Institute for Diagnostic and Interventional Imaging (IDII), in which Philips participates together with UMC Utrecht, University Utrecht, and TU Eindhoven. He is a member of the Supervisory Board of the European Institute of Innovation & Technology (EIT) Health, and a member of the European Scientific Panel for Health.
Hans joined Philips Research from Akzo Nobel Central Research in 1998. He has also worked as a (part-time) Professor at the Institute of Molecular Chemistry of the University of Amsterdam, and at the Public Works Department of the Dutch Ministry of Transport and Public Works in The Hague. He graduated with a PhD in physical chemistry from the Free University Amsterdam (thesis awarded with the Royal Dutch Shell prize), and was a post-doc at the Eidgenössische Technische Hochschule, Zürich, Switzerland. He worked as a lecturer at the Free University, the Free University Medical Center, and the University College of Swaziland in Kwaluseni while completing his studies. Hans has authored about 200 publications with an h-index of 42 (Google Scholar) and holds 10 granted US patents.
https://www.linkedin.com/in/hofstraat/
Foundation Medicine Access Innovation and PHC Lead, Pharma International, F. Hoffmann-La Roche
Chair of the “Funding Medical Technologies” group, MedTech Europe
Markus A. Ott is a Global Medical Technology Professional with more than twenty years successful experience in international/global commercial & non-commercial roles he has become a highly effective and creative industry leader with extensive knowledge of the healthcare market.
Currently he is leading the Market Access & Health Policy department at Roche Diagnostics International (CPS) based in Rotkreuz/Switzerland.
His passion are all aspects of his job but primarily Value Based Healthcare & the digitalization of our industry.
He is/has been a member of global Management teams for various companies and associations. So, Markus has been member of the Executive Board of MedTech Europe as well as the Swiss Diagnostic Association. He acted as Chair Elect and Executive Board Member of EPPOSI (European Platform for Patient's Organizations, Science & Industry). Currently he chairs the HTA IVD & Value of Diagnostics Working groups @ MedTech Europe.
Finally, he is author of multiple publications as well as chair, panelist and speaker at many global conferences.
Vice President Communications, Europe, Middle East & Africa
Medtronic
Creative, international and multi-cultural business, communications and public affairs executive, lawyer and entrepreneur with results-driven management experience in business development, corporate and public affairs, government relations, corporate social responsibility, crisis management, branding and positioning, stakeholder engagement, product and corporate marketing, across industries-- from healthcare to not-for profit. Specialties: Strategic corporate communications, corporate affairs, government relations, crisis and issues management, perception management, employee and change management communications, media relations, marketing communications, labor relations, industry engagement, corporate responsibility, compliance communications, issues advocacy, multicultural communications.
Currently working as Vice President Market Access, Latin America at Medtronic. Previously worked as Vice President of Public Affairs and Director Communications Latin America Region at Baxter, and had several managing positions at Burson-Marsteller in past.
Senior Director, Market Access
Roche Tissue Diagnostics, USA
Elizabeth received her undergraduate degrees at State University of New York and Master’s of Business at Wake Forest University – Babcock school of Business. She is currently Head of Global Market Access, Roche Tissue Diagnostics in Tucson, Arizona. She provides leadership oversight of Market Access projects, strategic health economics and pricing, reimbursement support for Roche affiliates concentrating on high medical value assays. She also oversees access management of External Quality Assessment program participation, and relevant guidelines and standards. Prior to her current role she has held other key positions within RTD that included launch optimization and commercialization of new FDA approved products.
Elizabeth has authored numerous publications and is frequent invited speaker at state, regional, national and international congresses. She is a voting member and committee representative with the Clinical Laboratory Standards Institute (CLSI) and member of the ISO/TC212 Clinical Laboratory Testing and in vitro Test Systems, US Technical Advisory Group, Advisor Histotechnology Committee, College of American Pathologists (CAP), board member of the Arizona Bioindustry Association and President of the Anatomic Pathology Patient Interest Association (APPIA).
Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany
Christian has an academic background in human medicine, biomedical sciences, health policy & health economics. Before joining Fresenius Medical Care, Christian worked in different strategic and management positions of a medium sized care provider in Germany. In Fresenius Medical Care he is heading the Health Economics, Market Access & Policy Affairs activities for Europe, Middle-East and Africa.
Global Director Scientific Communications | Medical Affairs
Medtronic, France
Patrice is a medical device industry expert with 25 years of experience in Clinical and Medical Affairs. He holds a Masters Degree in Pharmacology and a Masters Degree in Business Administration for Pharmaceutical and Biomedical Companies. After he joined Sofradim/Medtronic in 1998, he took the lead and established the clinical research department. Since 2012, he is the Leader of the Scientific Communication for Abdominal and Robotic Surgery. Prior to joining Medtronic, he spent almost 5 years as a clinical research manager at Biomatech, a consulting and testing company focused on medical devices. In addition, Patrice was an expert in numerous standards including ISO 14155, Medtech, and was a member of several task forces.
Program Director
Medtech4Health, Sweden
Mr Gårdebäck program director for the Swedish National Strategic Innovation program Medtech4Health which focus on financing of innovative projects and strategic collaborations, nationally and internationally within the medtech area. By acting as catalyst, Medtech4Health seek to encourage the increased implementation of medical technical solutions in healthcare, make healthcare more effective, and strengthen the Swedish medtech industry. This is done through awarding funding to different projects, through strategic investments, and by lobbying at different levels both inside and outside Sweden. The program is governemnet founded through the Swedish Innovation Agency VINNOVA and have a financing budget around 6 Million Euro / year.
Mr Gårdebäck has more than 25 years of experience in global international medtech companies like Siemens, Elekta, GE Medical systems and Medtronic. The last two Mr Gårdebäck held the position as CEO for the business in Sweden. He is also board member in several companies and has a technical degree as Master of Science in Physics from KTH, the Royal Institute of Technology. In addition to general management positions Mr Gårdebäck have experience working in R&D departments as well as project management and marketing & sales positions including tendering and healthpolicy related activities.
Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University
Driven with the passion to health economics, I have more than 20 years of academic and industry experience in the field of healthcare. Holding various Regional and Global leadership positions, I have been working extensively within public health sector as well as pharma and medtech industry.
After six years employment at the Kalmar County Council in Sweden, I held global and regional Health Economics & Outcomes Research (HEOR) positions at AstraZeneca and BiogenIdec respectively. At Bristol Myers Squibb and Lundbeck I lead Market Access teams in Central Eastern European (CEE) and Nordic Region. In the last five years, I gained experience with the pricing &reimbursement challenges in the field of medical devices. I supported Straub Medical as Global Market Access Lead. Before that, I was Senior Sales Director responsible for HEOR at GE Healthcare.
Since 2018 I am a Professor at the Kozminski University heading Health Economics & Healthcare Management Division (HeM). I am the leader of the International Master Program Health Economics & Big Data (HEBDA) financed by the EU research grant. In October 2020, I was nominated to the ISPOR’s Health Sciences Policy Council (HSPC). Since January 2020, I am chair elect of ISPOR Special Interest Group Digital Health as well.
My biggest strength is the market access planning for a successful pricing & reimbursement strategy. Knowledgably of HTA guidelines, DRG financing and hospital procurement pathways across EU & US settings, I will be able to advice on the optimal market entry that ensures the best differentiation of a given technology against alternative treatment options
Senior Vice President, Global Market Access
Inspire Medical Systems
In 2017, Kathy joined Inspire Medical Systems, a manufacturer of an implantable hypoglossal nerve stimulation device for treatment of obstructive sleep apnea, to lead the Reimbursement and Market Access function.
She has over 25 years of Medical Device industry experience and has led reimbursement teams both in Europe and the US. Prior to joining Inspire, Kathy lead US reimbursement and pricing teams for Boston Scientific, St. Jude Medical, and Medtronic. She lived in the Netherlands for several years, leading KCI Medical’s European reimbursement function.
Kathy holds a Bachelor of Science degree in Mechanical-Industrial Engineering from the University of Illinois, Urbana-Champaign, and an MBA from the University of Minnesota, Carlson School of Business in Minneapolis.
Senior Director DACH, Payers & Health Economics
Coloplast
Christian spent the first half of his career in the German Statutory Health Insurance, covering different positions and ended up with the project lead of one of the first huge Managed Care models in the country. As a consultant, Christian supported sickfunds to introduce the German DRG system and Managed Care approaches before he started with his first market access projects. Prior to joining Coloplast in 2017 he held different national and international market access positions at Johnson & Johnson, Accuray and in a pharmaceutical startup. Christian holds a Bachelor of Science degree in Health Communication and Healthcare Management. As a Director Payers & Health Economics at Coloplast, Christian is now responsible for Regulatory Affairs, Public Affairs and Payer Managenment.
Senior Manager, Global Pricing & Competitive Portfolio Analytics Team
Philips Healthcare
After finishing his European Finance and Accounting studies in Bremen, Germany (Dipl.-Betriebswirt) and Leeds; England (BA (Hons)) plus obtaining an MBA in Edinburgh (Scotland), Tobias Happel worked for almost 2 years as a consultant for financial Application at Oracle. For the last 17 years he was in different finance and pricing roles at Philips Medical in Böblingen (Germany) with growing responsibilities ending up in a global pricing responsibility in the Value Segment Solutions Equipment and MR Patient Care. In 2014 he was accredited as Certified Pricing Manager from the European Pricing Platform. Besides that, for the last 18 months he also led a value based pricing project in the MR Patient Care environment and is adapting some key learnings to other strategic value based pricing projects.
Sr. Director Marketing & Academy Europe
Arjo, Europe
Jan joined Arjo in January 2011 as Sales and Marketing Director for Arjo Netherlands. In 2015 Jan was appointed Country Manager Netherlands and in 2016 Managing Director BENELUX. In this position Jan grew the business and strengthened customer intimacy by the development of new business models like Pay per Patient, a customer web portal, track and trace solutions and consultative selling based on solutions. Jan holds a Commercial economics degree from the University of applied science ‘s-Hertogenbosch, Netherlands and is a Registered Marketer certified by the European Marketing Certification Foundation.
Hospital Economics - Sr. Manager Strategic Marketing Monitoring & Analytics and Therapeutic Care
Philips, Germany
Anne is currently working as a Hospital Economics Senior Segment Manager at Royal Philips in Germany. Her focus is to bring the voice of the economic stakeholders of the hospital in the solutions development, marketing and selling of the Monitoring & Analytics and Therapeutic Care businesses. She has been working at Philips for 6 years mostly in the marketing intelligence area and prior to that for other companies including Hewlett-Packard as a financial analyst at the start of her career. She holds a French Bachelor degree in Marketing and a Master in Business Administration with a major in finance from Cornell University.
Director Reimbursement Germany
CytoSorbents Corporation
Being a marketing expert with over a decade of international experience in the medical device industry, Franziska Preissing has been able to gather extensive experience, particularly in the field of introducing innovative products and therapies into intensive care and cardiac surgery. In the position of International Marketing Director of several medical device companies, as well working as a consultant, she has, over the years, acquired profound knowledge on reimbursement strategies and health economics, with a focus on how to proceed as a small and medium sized enterprise. Today Franziska Preissing is responsible for global reimbursement strategies and health economics at CytoSorbents Europe, who launched the CytoSorb adsorber, an extracorporeal therapy that enables innovative adsorption in SIRS (systemic inflammatory response syndrome) and sepsis patients.
CEO and Founder
ValueConnected
Ernesto is the Founder and Managing Director of ValueConnected. He has over 23
years of experience leading healthcare strategies to drive access and expansion for new products, developing value propositions for both public and private stakeholders and assessing global market opportunities. He has worked for both government agencies and global healthcare companies in roles ranging from strategic marketing and new product development to health economics and reimbursement. Ernesto has led several Market Access projects across Europe, US, Middle East and Latin America. Ernesto holds an MBA from the University of Texas at Austin and is fluent in English, Spanish and Portuguese.
Director of European Operations
ValueConnected
Ben is the Director of European Operations at ValueConnected and has more than 10 years of extensive experience with both pre and post-launch activities, with a strong focus on health technology assessment, market assessment and purchasing processes. He has managed several international projects within Western and Eastern Europe.
He has performed numerous analyses to guide sales and pricing of medical technologies as well as reimbursement applications by using health economics to drive commercial messages.
Ben has an in-depth knowledge about Germany, Switzerland and Austria with an extensive network of contacts with doctors, reimbursement authorities and purchasing departments within these countries. He graduated in Mathematics at the Albert-Ludwigs-Universität Freiburg im Breisgau in 2009 and is fluent in both German and English.
President
Boston Healthcare, USA
Mr. Ferrara has over 18 years of experience in life sciences consulting, working with biopharmaceutical, medical device, diagnostics, and health care IT clients in market and business development strategy. He leads the global consulting team with practice areas in reimbursement and pricing, health economics, market analysis, and business development strategy. Mr. Ferrara has extensive experience in the development of novel business approaches designed to capture evidence-based value for innovation health care technologies. Mr. Ferrara writes and speaks extensively on the subject of the value of medical technology innovation, with particular focus on pharmacogenomics, specialty pharmaceuticals, and novel therapeutic devices. Prior to his consulting role, Mr. Ferrara led a joint venture between Boston Healthcare and a non-profit research organization focused on a global electronic medical record network for the purposes of clinical trials and health outcomes research. Mr. Ferrara completed undergraduate studies at the University of Cincinnati and received a master’s degree from Harvard University.
Vice President
Boston Healthcare
Mr. Wenthold has 15 years of experience providing consulting services to the biopharmaceutical, medical device and diagnostic companies on commercialization and market access strategy. Mr. Wenthold’s particular focus is global pricing, reimbursement, and market access for innovative medical technologies. He has substantial experience in global markets and managed Boston Healthcare Associates European HQ office in Berlin from 2013-2014. Mr Wenthold has been responsible for international operations since 2009. Mr Wenthold brings an in-depth understanding of global payers and health systems and a rigorous research methodology to properly assess investment opportunities and risks. He has experience supporting several due diligence transactions, embedding pricing and reimbursement risk, and building additional evidence investment and infrastructure development into go/ no-go and valuation decisions. He advises start-up and early stage companies as well as large multinationals and has experience across disease types, settings of care and global markets.
Principal and Founder
Hull Associates
Stephen Hull is Principal and Founder of Hull Associates LLC, a specialized global reimbursement and market access consultancy. He and his firm leverage over 25 years of experience in US and global reimbursement and in-market expertise on behalf of pharma, medical device and diagnostics Clients. Prior to forming Hull Associates in 2007, he served as SVP for Global Reimbursement at AdvaMed, in Washington, D.C. and as chair of the ISPOR Medical Devices Council. Stephen holds a Master’s degree in health policy from the Johns Hopkins Bloomberg School of Public Health, and a bachelor’s degree in international relations and French from Colgate University.
Director, Life Sciences
Huron Consulting
Sotiris has been working with market access, marketing and policy teams of Fortune 500 Life science companies to assess health system trends and stakeholder needs, develop value propositions for innovative medical technologies and develop Access strategy.
Prior to joining Huron, Sotiris held senior positions at Boston Healthcare Associates and GfK Market Access where he lead teams on various commercial, pricing & market access and marketing engagements at the product- and portfolio- level.
Sotiris started his consulting career at IMS Consulting group working in the Pricing and Market Access practice.
Sotiris has expert working knowledge in various quantitative and qualitative methodologies and research tools (e.g., conjoint, MaxDiff, MCDA, virtual ad boards, IDIs, scorecards).
Focus areas
• Access strategy
• Payer and Provider dynamics
• Value proposition development
• Innovative Business models
Education
• PhD in Strategic Management, Warwick Business School (Economic & Social Research Council fellow)
• M.Sc. International Health Management, Imperial College London